Figure 1.

Treatment algorithm for MF. *High-risk features include cytogenetic markers: complex karyotype, −7, i(17q), inv(3)/3q21, 12p-/12p11.2, 11q-/11q23, other autosomal trisomies not including +8 or +9, mutations in ASXL1, EZH2, SRSF2, IDH1/2, U2AF1, TP53, as well as aggressive clinical features (rapidly increasing circulating blasts or leukocytosis, severe symptoms, or splenomegaly). Allo-HCT, allogeneic hematopoietic cell transplantation; DIPSS, Dynamic International Prognostic Scoring System⁵⁴; DIPSS-Plus⁵⁵; EPO, erythropoietin level; MIPSS70, Mutation-Enhanced International Prognostic Score System⁵⁶; MIPSS70-Plus v2⁵⁷; MYSEC-PM, MF secondary to PV and ET-prognostic Model.⁵⁸